Naturally Occurring Molecule Rivals Ozempic in Weight Loss
- Researchers have identified a novel peptide,named BRP,that demonstrates notable potential in reducing food intake adn promoting fat loss.
- The discovery process relied heavily on advanced computational tools.
- While the GLP-1 peptide increased neuronal cell activity threefold, a small peptide consisting of just 12 amino acids boosted the cells’ activity tenfold.
Novel Peptide BRP Shows Promise in Obesity Treatment
Table of Contents
- Novel Peptide BRP Shows Promise in Obesity Treatment
- BRP: A Novel Peptide Therapy for Obesity – Your Questions Answered
- What is BRP and how was it discovered?
- How does BRP compare to GLP-1 and Semaglutide?
- What are the effects of BRP on animal models?
- Are there any observed side effects of BRP in animal models?
- How does BRP work? What are its action pathways?
- What is the potential of BRP as an anti-obesity treatment?
- What are the next steps in BRP research?
- Who is involved in the BRP research?
- What funding sources support this research?
- Are there any conflicts of interest to be aware of?
Researchers have identified a novel peptide,named BRP,that demonstrates notable potential in reducing food intake adn promoting fat loss. This revelation could pave the way for new and more effective anti-obesity medications.
Discovery of BRP: A New Hope for obesity Management
The discovery process relied heavily on advanced computational tools. according to Svensson, “The algorithm was absolutely key to our findings.” The Peptide Predictor tool predicted that prohormone convertase 1/3 would generate 2,683 unique peptides from 373 proteins. The focus then shifted to identifying sequences with biological activity in the brain. Researchers Coassolo and Svensson screened 100 peptides, including GLP-1, for their ability to activate lab-grown neuronal cells.
BRP Outperforms GLP-1 in Activating Neuronal Cells
While the GLP-1 peptide increased neuronal cell activity threefold, a small peptide consisting of just 12 amino acids boosted the cells’ activity tenfold. This new peptide was named BRP, derived from its parent prohormone, BPM/retinoic acid inducible neural specific 2, or BRINP2 (BRINP2-related-peptide).
impact of BRP on Animal Models
The effects of BRP were tested on lean mice and minipigs, the latter chosen for their metabolic similarities to humans. An intramuscular injection of BRP prior to feeding reduced food intake by up to 50% in both animal models over the next hour. Furthermore,obese mice treated with daily injections of BRP for 14 days experienced an average weight loss of 3 grams,primarily due to fat loss,while control animals gained about 3 grams. These mice also showed improved glucose and insulin tolerance.
| Animal Model | Treatment | result |
|---|---|---|
| Lean Mice & Minipigs | Intramuscular BRP Injection | Up to 50% reduction in food intake |
| Obese Mice | Daily BRP Injections (14 days) | Average loss of 3 grams (fat loss) |
No Adverse Behavioral Changes Observed
Behavioral studies on the mice and pigs revealed no significant differences in movements, water intake, anxiety-like behavior, or fecal production. Additional studies of physiological and brain activity indicated that BRP activates metabolic and neuronal pathways distinct from those activated by GLP-1 or semaglutide.
Future Research Directions
Researchers are now focused on identifying the cell-surface receptors that bind BRP and further dissecting its action pathways. They are also exploring methods to prolong the peptide’s effects, aiming for a more convenient dosing schedule if BRP proves effective in regulating human body weight.
The Urgent Need for Effective Obesity Treatments
The search for effective obesity treatments remains a critical area of research. As Svensson notes, “The lack of effective drugs to treat obesity in humans has been a problem for decades. Nothing we’ve tested before has compared to semaglutide’s ability to decrease appetite and body weight. We are very eager to learn if it is indeed safe and effective in humans.”
Collaborative Effort and Funding
Researchers from the University of California, Berkeley; the University of Minnesota; and the University of British Columbia contributed to the work.
The study received funding from various sources, including the National Institutes of Health (grants R01DK125260, P30DK116074, K99AR081618 and GM113854), the SPARK Translational Research Program at Stanford, Stanford Bio-X, the Stanford Maternal and Child Health Research Institute, the American Heart Association, a Stanford Medicine Dean’s Fellowship Award, the Carlsberg Foundation, and the Wu Tsai Human Performance Alliance.
Disclaimer: Svensson and Coassolo are inventors on patents regarding BRP peptides for metabolic disorders. Svensson is a co-founder of Merrifield Therapeutics.
BRP: A Novel Peptide Therapy for Obesity – Your Questions Answered
This article explores the exciting potential of BRP, a novel peptide showing promise in obesity treatment. We’ll answer your questions and discuss its revelation, effects, and future.
What is BRP and how was it discovered?
BRP stands for BRINP2-related peptide. It’s a novel 12-amino acid peptide derived from the prohormone BPM/retinoic acid inducible neural specific 2 (BRINP2).
Discovery:
Researchers used a “Peptide Predictor” tool to analyze 373 proteins and predict 2,683 unique peptides generated by prohormone convertase 1/3.
They focused on identifying sequences with biological activity in the brain.
Coassolo and Svensson screened 100 peptides, including GLP-1, for their ability to activate lab-grown neuronal cells.
BRP outperformed GLP-1,increasing neuronal cell activity tenfold compared to GLP-1’s threefold increase. This significant difference pointed to BRP’s potential.
How does BRP compare to GLP-1 and Semaglutide?
While both BRP and GLP-1 activate neuronal cells, BRP shows a significantly stronger response in initial lab tests (tenfold increase in activation vs. threefold for GLP-1). Moreover, studies suggest BRP activates metabolic and neuronal pathways distinct from those activated by GLP-1 or semaglutide.
What are the effects of BRP on animal models?
BRP has shown promising results in animal studies:
Reduced Food Intake: Intramuscular injections of BRP in lean mice and minipigs reduced food intake by up to 50% within an hour.
Weight Loss: obese mice treated with daily BRP injections for 14 days experienced an average weight loss of 3 grams, primarily from fat loss. Control animals gained weight.
Improved Glucose and Insulin Tolerance: Obese mice treated with BRP also showed improvements in glucose and insulin tolerance.
| Animal Model | Treatment | Result |
| :——————- | :—————————– | :—————————————— |
| Lean Mice & Minipigs | Intramuscular BRP Injection | Up to 50% reduction in food intake |
| Obese Mice | Daily BRP Injections (14 days) | Average loss of 3 grams (primarily fat loss) |
Are there any observed side effects of BRP in animal models?
So far, behavioral studies in mice and pigs have not revealed any significant adverse effects:
No differences in movements, water intake, or anxiety-like behavior were observed.
Fecal production remained normal.
How does BRP work? What are its action pathways?
Researchers are still working to fully understand BRP’s mechanism of action. They are actively trying to:
Identify cell-surface receptors: Determine which receptors BRP binds to.
Dissect action pathways: Elucidate the specific signaling pathways activated by BRP within cells.
The initial study showed that BRP activates different pathways than GLP-1 and semaglutide.
What is the potential of BRP as an anti-obesity treatment?
BRP’s ability to reduce food intake, promote fat loss, and improve glucose and insulin tolerance in animal models suggests it has significant potential as an anti-obesity treatment. Svensson notes that existing treatments haven’t matched semaglutide’s results in appetite and weight reduction, emphasizing the importance of determining BRP’s safety and effectiveness in humans.
What are the next steps in BRP research?
Future research directions include:
Identifying the specific cell-surface receptors that bind to BRP.
Further dissecting BRP’s action pathways to understand how it works at a molecular level.
Exploring methods to prolong the peptide’s effects for a more convenient dosing schedule.
Most importantly, determining if BRP is safe and effective in humans through clinical trials.
Who is involved in the BRP research?
The research is a collaborative effort involving researchers from:
University of California, Berkeley
University of Minnesota
University of British Columbia
What funding sources support this research?
The study received funding from various prominent sources, including:
National Institutes of Health (NIH)
SPARK Translational Research Program at Stanford
Stanford Bio-X
Stanford Maternal and Child Health Research Institute
American Heart Association
Stanford Medicine Dean’s Fellowship Award
Carlsberg Foundation
Wu Tsai Human Performance Alliance
Are there any conflicts of interest to be aware of?
Yes, it’s important to note that Svensson and Coassolo are inventors on patents regarding BRP peptides for metabolic disorders. Svensson is also a co-founder of Merrifield Therapeutics. This disclosure ensures openness regarding potential biases.